Masimo Corporation Board of Directors Authorizes Management to Evaluate the Separation of Consumer Business
2024年3月23日 - 5:05AM
ビジネスワイヤ(英語)
Masimo (NASDAQ: MASI), a global leader in noninvasive monitoring
technologies and audio products, today announced that its Board of
Directors has authorized management to evaluate a proposed
separation of its consumer business. The Board and management will
evaluate the proposed structure of the separation. Masimo expects
that the separation will include its consumer audio and consumer
health products, including the Stork baby monitor and the Freedom
smart watch and band. Masimo will retain its professional
healthcare and telehealth products. Masimo expects that this will
improve the profitability of the healthcare business. Joe Kiani is
expected to remain Chairman and CEO of Masimo and to be named
Chairman of the newly created company. Masimo will seek to complete
the separation as soon as feasible, subject to completion of due
diligence, completion of definitive agreements, submission and
clearance of filings with the Securities and Exchange Commission
and the receipt of other applicable regulatory approvals.
“I truly believe there is tremendous opportunity to increase not
just the lifespan but the healthspan of people by taking healthcare
into the home,” said Mr. Kiani. “We have unique and necessary
technologies to make what I’ve been calling 22nd Century healthcare
happen in the next few years. I proposed a separation of the
consumer business in January and the Board has agreed to move
forward. This approach is expected to maximize shareholder value as
well as give both Masimo healthcare and the new consumer business
the best path for success.”
Masimo is also reaffirming its financial guidance for the first
quarter and fiscal year 2024.
About Masimo
Masimo (NASDAQ: MASI) is a global medical technology company
that develops and produces a wide array of industry-leading
monitoring technologies, including innovative measurements,
sensors, patient monitors, and automation and connectivity
solutions. In addition, Masimo Consumer Audio is home to eight
legendary audio brands, including Bowers & Wilkins, Denon,
Marantz, and Polk Audio. Our mission is to improve life, improve
patient outcomes, and reduce the cost of care. Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry,
introduced in 1995, has been shown in over 100 independent and
objective studies to outperform other pulse oximetry technologies.3
Masimo SET® has also been shown to help clinicians reduce severe
retinopathy of prematurity in neonates,4 improve CCHD screening in
newborns,5 and, when used for continuous monitoring with Masimo
Patient SafetyNet™ in post-surgical wards, reduce rapid response
team activations, ICU transfers, and costs.6-9 Masimo SET® is
estimated to be used on more than 200 million patients in leading
hospitals and other healthcare settings around the world,1 and is
the primary pulse oximetry at 9 of the top 10 hospitals as ranked
in the 2022-23 U.S. News and World Report Best Hospitals Honor
Roll.2 In 2005, Masimo introduced rainbow® Pulse CO-Oximetry
technology, allowing noninvasive and continuous monitoring of blood
constituents that previously could only be measured invasively,
including total hemoglobin (SpHb®), oxygen content (SpOC™),
carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth
Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen Reserve
Index (ORi™). In 2013, Masimo introduced the Root® Patient
Monitoring and Connectivity Platform, built from the ground up to
be as flexible and expandable as possible to facilitate the
addition of other Masimo and third-party monitoring technologies;
key Masimo additions include Next Generation SedLine® Brain
Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography
with NomoLine® sampling lines. Masimo’s family of continuous and
spot-check monitoring Pulse CO-Oximeters® includes devices designed
for use in a variety of clinical and non-clinical scenarios,
including tetherless, wearable technology, such as Radius-7®,
Radius PPG®, and Radius VSM™, portable devices like Rad-67®,
fingertip pulse oximeters like MightySat® Rx, and devices available
for use both in the hospital and at home, such as Rad-97® and the
Masimo W1® medical watch. Masimo hospital and home automation and
connectivity solutions are centered around the Masimo Hospital
Automation™ platform, and include Iris® Gateway, iSirona™, Patient
SafetyNet, Replica®, Halo ION®, UniView®, UniView :60™, and Masimo
SafetyNet®. Its growing portfolio of health and wellness solutions
includes Radius T°® and Masimo W1 Sport. Additional information
about Masimo and its products may be found at www.masimo.com.
Published clinical studies on Masimo products can be found at
professional.masimo.com/evidence/featured-studies/feature/. RPVi
has not received FDA 510(k) clearance and are not available for
sale in the United States. The use of the trademark Patient
SafetyNet is under license from University HealthSystem
Consortium.
RPVi has not received FDA 510(k) clearance and is not available
for sale in the United States. The use of the trademark Patient
SafetyNet is under license from University HealthSystem
Consortium.
References
- Estimate: Masimo data on file.
-
http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.
- Published clinical studies on pulse oximetry and the benefits
of Masimo SET® can be found on our website at
http://www.masimo.com. Comparative studies include independent and
objective studies which are comprised of abstracts presented at
scientific meetings and peer-reviewed journal articles.
- Castillo A et al. Prevention of Retinopathy of Prematurity in
Preterm Infants through Changes in Clinical Practice and SpO2
Technology. Acta Paediatr.2011 Feb;100(2):188-92.
- de-Wahl Granelli A et al. Impact of pulse oximetry screening on
the detection of duct dependent congenital heart disease: a Swedish
prospective screening study in 39,821 newborns. BMJ.2009;Jan
8;338.
- Taenzer A et al. Impact of pulse oximetry surveillance on
rescue events and intensive care unit transfers: a before-and-after
concurrence study. Anesthesiology. 2010:112(2):282-287.
- Taenzer A et al. Postoperative Monitoring – The Dartmouth
Experience. Anesthesia Patient Safety Foundation Newsletter.
Spring-Summer 2012.
- McGrath S et al. Surveillance Monitoring Management for General
Care Units: Strategy, Design, and Implementation. The Joint
Commission Journal on Quality and Patient Safety. 2016
Jul;42(7):293-302.
- McGrath S et al. Inpatient Respiratory Arrest Associated With
Sedative and Analgesic Medications: Impact of Continuous Monitoring
on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14
Mar. DOI: 10.1097/PTS.0000000000000696.
Forward-Looking Statements - Masimo
This press release includes forward-looking statements as
defined in Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, in connection with the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, among others, statements
regarding the proposed separation of Masimo’s consumer business,
including the potential timing and structure thereof, the proposed
timing for providing an update regarding the proposed separation
and the expectation that the proposed separation will maximize
shareholder value or be the best path for success and the statement
regarding Masimo’s first quarter 2024 financial guidance. These
forward-looking statements are based on current expectations about
future events affecting us and are subject to risks and
uncertainties, all of which are difficult to predict and many of
which are beyond our control and could cause our actual results to
differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors,
including, but not limited to: risks related to: the ability to
effect the transactions described above and to meet the conditions
related thereto; the ability of the separated business to be
successful; potential uncertainty during the pendency of the
transactions that could affect Masimo’s financial performance; the
possibility that the transactions will not be completed within the
anticipated time period or at all; the possibility that the
transactions will not achieve their intended benefits; the
possibility of disruption, including changes to existing business
relationships, disputes, litigation or unanticipated costs in
connection with the transactions; impact on our employees;
uncertainty of the expected financial performance of Masimo prior
to and following completion of the transactions; negative effects
of the announcement or pendency of the transactions on the market
price of the Company's securities and/or on the financial
performance of Masimo; evolving legal, regulatory and tax regimes;
changes in general economic and/or industry specific conditions;
actions by third parties, including government agencies; as well as
other factors discussed in the “Risk Factors” section of our most
recent reports filed with the Securities and Exchange Commission
(“SEC”), which may be obtained for free at the SEC’s website at
www.sec.gov. Although we believe that the expectations reflected in
our forward-looking statements are reasonable, we do not know
whether our expectations will prove correct. All forward-looking
statements included in this press release are expressly qualified
in their entirety by the foregoing cautionary statements. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of today’s date. We do not
undertake any obligation to update, amend or clarify these
statements or the “Risk Factors” contained in our most recent
reports filed with the SEC, whether as a result of new information,
future events or otherwise, except as may be required under the
applicable securities laws.
Masimo, SET, Signal Extraction Technology, Improving Patient
Outcome and Reducing Cost of Care... by Taking Noninvasive
Monitoring to New Sites and Applications, rainbow, SpHb, SpOC,
SpCO, SpMet, PVI and ORI are trademarks or registered trademarks of
Masimo Corporation
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240322542751/en/
Investor Contact: Eli Kammerman (949) 297-7077
ekammerman@masimo.com
Media Contact: Evan Lamb (949) 396-3376
elamb@masimo.com
Masimo (NASDAQ:MASI)
過去 株価チャート
から 4 2024 まで 5 2024
Masimo (NASDAQ:MASI)
過去 株価チャート
から 5 2023 まで 5 2024